HCPCS Codes Similar to M1472

HCPCS Codes Similar to “M1472” Code.
Patient did not receive recommended doses of hepatitis b vaccination based on age

M1468 Patient received recommended doses of hepatitis b vaccination based on age Code added date: 20260101 Code effective date: 20260101 TXT \| PDF \| XML \| JSON	M1238 Documentation that administration of second recombinant zoster vaccine could not occur during the performance period due to the recommended 2-6 month interval between doses (i.e, first dose received after october 31) Code added date: 20240101 Code effective date: 20240101 TXT \| PDF \| XML \| JSON
G2162 Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement period Code added date: 20200101 Code effective date: 20210101 TXT \| PDF \| XML \| JSON	M1176 Patient did not receive two doses of the herpes zoster recombinant vaccine (at least 28 days apart) on october 20, 2017, through the end of the measurement period Code added date: 20230101 Code effective date: 20260101 TXT \| PDF \| XML \| JSON
M0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring Code added date: 20211208 Code effective date: 20241213 TXT \| PDF \| XML \| JSON	M0221 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency Code added date: 20211208 Code effective date: 20241213 TXT \| PDF \| XML \| JSON
Q0220 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg Code added date: 20211208 Code effective date: 20241213 TXT \| PDF \| XML \| JSON	Q0221 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg Code added date: 20220224 Code effective date: 20241213 TXT \| PDF \| XML \| JSON
M0240 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses Code added date: 20210730 Code effective date: 20241213 TXT \| PDF \| XML \| JSON	M0241 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses Code added date: 20210730 Code effective date: 20241213 TXT \| PDF \| XML \| JSON
G2160 Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period Code added date: 20200101 Code effective date: 20210101 TXT \| PDF \| XML \| JSON	M1174 Patient received at least two doses of the herpes zoster recombinant vaccine (at least 28 days apart) on october 20, 2017, through the end of the measurement period Code added date: 20230101 Code effective date: 20260101 TXT \| PDF \| XML \| JSON
M1063 Patients receiving high doses of immunosuppressive therapy Code added date: 20190101 Code effective date: 20210101 TXT \| PDF \| XML \| JSON	G2156 Patient did not receive at least one td vaccine or one tdap vaccine between nine years prior to the start of the measurement period and the end of the measurement period; or have history of at least one of the following contraindications any time during or before the measurement period: anaphylaxis due to tdap vaccine, anaphylaxis due to td vaccine or its components; encephalopathy due to tdap or td vaccination (post tetanus vaccination encephalitis, post diphtheria vaccination encephalitis or post pertussis vaccination encephalitis.) Code added date: 20200101 Code effective date: 20210101 TXT \| PDF \| XML \| JSON